Company intelligence / Profile preview

ACM

Singapore, Central Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

ACM Biolabs’ lead program, ACM-001 (COVID-19 booster vaccine), completed Phase 1 showing safety and early immunogenicity, with no serious adverse events. The ATP™ platform is clinically validated for the thermostable delivery of mRNA and immunomodulators, including a TLR9 agonist being evaluated in cancer immunotherapy trials[1][2][3].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Polymer-lipid hybrid nanoparticleNon-viral deliverySmall moleculemRNA-based drugsOligonucleotideProtein
Industry: Biotech

Partnerships

CEPI (Coalition for Epidemic Preparedness Innovations; backing for thermostable mRNA platform)National Cancer Center Singapore (IIT clinical collaborations)

Beyond the preview

Go deeper on ACM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACM.

Explore the full profile